EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
Biotech Showcase 2015 EBD Group Demy-Colton
Share/Follow Us
Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

Biotech Showcase™ 2016 Press Releases

News for Biotech Showcase™ 2016 will be available soon.

January 27, 2015Biotech Showcase™ 2015 surpasses all previous investor attendance, partnering numbers The seventh annual Biotech Showcase investor conference wrapped up the week of January 12 in San Francisco with the highest number of delegates in attendance since its founding. More than 2,100 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives attended from...  more ►

January 2, 2015Biotech Showcase™ 2015 kicks off in one week
Over 2,000 life science executive dealmakers expected to attend
The seventh annual Biotech Showcase investor conference takes place in just over one week on January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square. Biotech Showcase is an investor conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and ph...  more ►

November 18, 2014Seventh Annual Biotech Showcase™ to be held in San Francisco January 12–14, 2015-- Record number of Life Science Investor meetings expected
The seventh annual Biotech Showcase investor conference will be held January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square. The event brings executive-level delegates representing top public and private investment firms with the goal to meet management teams of biotechnology and life science companies, including therapeutic companies, sp...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

August 29, 2015 HSCI fosters broad collaboration At the Harvard Stem Cell Institute (HSCI), "Partnering is important at all levels," emphasized Brock Reeve, executive director. That impetus is important not just in the sciences, but also among foundations, large and small companies and investors throughout the life sciences community. more ►

August 29, 2015 RA Capital: Flexibility builds innovation Flexibility is the watchword for investment at RA Capital Management. As Peter Kolchinsky, managing director, explained, "Investors should be as flexible as possible. Therefore, we're a crossover fund manager. We invest in biotechnology companies whether they are public or private companies and, increasingly, are putting our efforts into company formation." more ►

August 28, 2015 EBD partnering data dissected If you have attended any of our events, such as BIO-Europe┬«, then you know that they are a hive of partnering activity. Deals are plotted, shaped and consummated as thousands of executives shuttle between one-to-one meetings. If you are like us, then you are probably wondering which companies from what sector are getting the most attention.To get some answers, we asked IMS Health Capital (IMSHC), the investment banking arm of IMS Health, to analyze partnering data from our most recent conferences. more ►

August 8, 2015 Johnson & Johnson Innovation aims for disruption Johnson & Johnson Innovation, Boston, has high expectations for itself and its partners. "We're looking for ideas that will make a tremendous difference in patients' lives, not merely incremental progress," said Robert G. Urban, PhD, head of Johnson & Johnson Innovation, Boston. To do that, "we take advantage of the deep science emerging around us to develop bold platforms that make a big difference. more ►

July 21, 2015 Patient-centric Baxalta capitalizes on Cambridge When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 billion in annual revenues, 16,000 employees, operations in 100 countries and USD 600 million invested in R&D, it focuses its assets tightly on the patient experience and expects its partners to do the same. more ►



Arrow Up


 
 

Follow this event: Follow us on Twitter
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD Group, Inc.
Privacy Policy and Cookies
Terms of Use